PL2919815T3 - Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego - Google Patents

Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego

Info

Publication number
PL2919815T3
PL2919815T3 PL13801824T PL13801824T PL2919815T3 PL 2919815 T3 PL2919815 T3 PL 2919815T3 PL 13801824 T PL13801824 T PL 13801824T PL 13801824 T PL13801824 T PL 13801824T PL 2919815 T3 PL2919815 T3 PL 2919815T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
composition containing
calcium channel
channel blocker
ace inhibitor
Prior art date
Application number
PL13801824T
Other languages
English (en)
Inventor
Elżbieta Turczyn
Original Assignee
Adamed Pharma Spolka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49724636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2919815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamed Pharma Spolka Akcyjna filed Critical Adamed Pharma Spolka Akcyjna
Publication of PL2919815T3 publication Critical patent/PL2919815T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13801824T 2012-11-15 2013-11-12 Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego PL2919815T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
EP13801824.7A EP2919815B1 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
PCT/IB2013/060069 WO2014076632A1 (en) 2012-11-15 2013-11-12 A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker

Publications (1)

Publication Number Publication Date
PL2919815T3 true PL2919815T3 (pl) 2018-01-31

Family

ID=49724636

Family Applications (2)

Application Number Title Priority Date Filing Date
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
PL13801824T PL2919815T3 (pl) 2012-11-15 2013-11-12 Kompozycja farmaceutyczna zawierająca inhibitor ace i bloker kanału wapniowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL401632A PL227900B1 (pl) 2012-11-15 2012-11-15 Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję

Country Status (17)

Country Link
EP (1) EP2919815B1 (pl)
AU (1) AU2013346397B2 (pl)
BR (1) BR112015010119A2 (pl)
EA (1) EA027568B1 (pl)
ES (1) ES2650468T3 (pl)
HR (1) HRP20171863T1 (pl)
HU (1) HUE035163T2 (pl)
MX (1) MX353689B (pl)
MY (1) MY170451A (pl)
PH (1) PH12015501036B1 (pl)
PL (2) PL227900B1 (pl)
PT (1) PT2919815T (pl)
RS (1) RS56664B1 (pl)
SG (1) SG11201503441XA (pl)
UA (1) UA114439C2 (pl)
WO (1) WO2014076632A1 (pl)
ZA (1) ZA201504265B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275432A1 (en) * 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Dosage form with ace inhibitor
PT4103158T (pt) * 2020-02-10 2024-11-07 Adamed Pharma S A Composição que compreende ramipril e indapamida
GB2595203A (en) * 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5093129A (en) 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
BR0003282A (pt) 2000-07-14 2002-02-26 Libbs Farmaceutica Ltda Associação farmacêutica para tratamento da hipertenção arterial e prevenção de doenças cardiovasculares outras, como infarto do miocárdio, acidente vascular cerebral e insuficiências cardìaca e renal
CA2357982A1 (en) 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
EA007981B1 (ru) 2002-01-15 2007-02-27 Актавис Груп Хф. Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
US20030215526A1 (en) 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US20050181055A1 (en) 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
LT1729739T (lt) 2004-03-29 2016-11-10 Les Laboratoires Servier Kietos farmacinės kompozicijos gamybos būdas
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
AU2006224161A1 (en) * 2005-03-15 2006-09-21 Lupin Limited Pharmaceutical compositions of amlodipine and benazepril
WO2007040511A1 (en) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CA2628955A1 (en) 2005-11-07 2007-05-18 Edward S. Wilson Compositions of stabilized ramipril in combination with another active agent
WO2008065485A2 (en) 2006-10-19 2008-06-05 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
CA2790817A1 (en) * 2010-02-24 2011-09-01 Sanofi-Aventis Deutschland Gmbh Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation

Also Published As

Publication number Publication date
HUE035163T2 (en) 2018-05-02
EA201590529A1 (ru) 2015-09-30
PT2919815T (pt) 2017-12-11
ES2650468T3 (es) 2018-01-18
HK1213807A1 (en) 2016-07-15
PL227900B1 (pl) 2018-01-31
SG11201503441XA (en) 2015-05-28
MY170451A (en) 2019-07-31
HRP20171863T1 (hr) 2018-01-12
UA114439C2 (uk) 2017-06-12
RS56664B1 (sr) 2018-03-30
EP2919815A1 (en) 2015-09-23
ZA201504265B (en) 2017-11-29
AU2013346397A1 (en) 2015-06-18
EP2919815B1 (en) 2017-09-06
AU2013346397B2 (en) 2017-09-14
BR112015010119A2 (pt) 2017-07-11
MX2015006122A (es) 2015-08-05
EA027568B1 (ru) 2017-08-31
WO2014076632A1 (en) 2014-05-22
PH12015501036B1 (en) 2018-12-19
PH12015501036A1 (en) 2015-08-17
MX353689B (es) 2018-01-23
PL401632A1 (pl) 2014-05-26

Similar Documents

Publication Publication Date Title
IL245326B (en) pharmaceutical preparation
PL2920149T3 (pl) Związki 3-aminocykloalkilowe jako inhibitory ror-gamma-t oraz ich zastosowania
IL231963A0 (en) Blood thinners
AP2014007835A0 (en) Oxazolidin-2-one compounds and uses thereof as P13KS inhibitors
IL231962A0 (en) Hemostatic drug
LT2619182T (lt) Farmacinė kompozicija
IL225457A0 (en) Pharmaceutical composition
ZA201501394B (en) Coated pharmaceutical composition containing regorafenib
PL2758052T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
ZA201302108B (en) Pharmaceutical compositions containing a dgat1 inhibitor
PT2579858E (pt) Composição farmacêutica que contém ivabradina
SG10201509573VA (en) Pharmaceutical composition useful for adhesion prevention or hemostasis
GB201010453D0 (en) Pharmaceutical composition
ZA201501897B (en) A pharmaceutical composition
ZA201504265B (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
EP2851074A4 (en) ANALGETIC PHARMACEUTICAL COMPOSITION
GB201001911D0 (en) Pharmaceutical composition
EP2785343A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
ZA201202951B (en) Pharmaceutical composition containing a phenocarbamate acetylcholinesterase inhibitor
GB201221367D0 (en) A pharmaceutical composition
GB201019775D0 (en) Pharmaceutical composition